Apart from ALS, preclinical studies present that delivery of VEGF to the brain is therapeutic in AD, PD, and HD (Yasuhara et al., 2005; Ellison et al., 2013; Herran et al., 2013; Religa et al., 2013; Garcia et al., 2014). Here, VEGFA is linked to Parkinson disease.